Ophthalmology. Retina最新文献

{"title":"Decreased Macular Choriocapillaris Perfusion Correlates with Contrast Sensitivity Function in Dry Age-Related Macular Degeneration","authors":"Francesco Romano MD ,&nbsp;Filippos Vingopoulos MD ,&nbsp;Melissa Yuan MD ,&nbsp;Xinyi Ding MD ,&nbsp;Mauricio Garcia MS ,&nbsp;Ioanna Ploumi MSc ,&nbsp;Jocelyn Rodriguez MD ,&nbsp;Itika Garg MD ,&nbsp;Jack H. Tracy MS ,&nbsp;Augustine Bannerman BSc ,&nbsp;Hanna Choi MS ,&nbsp;Isabella Stettler MS ,&nbsp;Cade Bennett BSc ,&nbsp;Katherine M. Overbey BSc ,&nbsp;Inês Laìns MD, PhD ,&nbsp;Leo A. Kim MD, PhD ,&nbsp;Demetrios G. Vavvas MD, PhD ,&nbsp;Deeba Husain MD ,&nbsp;Joan W. Miller MD ,&nbsp;John B. Miller MD","doi":"10.1016/j.oret.2024.06.005","DOIUrl":"10.1016/j.oret.2024.06.005","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the relationships between contrast sensitivity (CS), choriocapillaris perfusion, and other structural OCT biomarkers in dry age-related macular degeneration (AMD).</div></div><div><h3>Design</h3><div>Cross-sectional, observational study.</div></div><div><h3>Participants</h3><div>One hundred AMD eyes (22 early, 52 intermediate, and 26 late) from 74 patients and 45 control eyes from 37 age-similar subjects.</div></div><div><h3>Methods</h3><div>All participants had visual acuity (VA) assessment, quantitative CS function (qCSF) testing, macular OCT, and 6 × 6-mm swept-source OCT angiography scans on the same day. OCT volumes were analyzed for subretinal drusenoid deposits and hyporeflective drusen cores, and to measure thickness of the outer nuclear layer. OCT angiography scans were utilized to calculate drusen volume and inner choroid flow deficit percentage (IC-FD%), and to measure the area of choroidal hypertransmission defects (HTDs). Inner choroid flow deficit percentage was measured from a 16-μm thick choriocapillaris slab after compensation and binarization with Phansalkar’s method. Generalized linear mixed-effects models were used to evaluate the associations between functional and structural variables.</div></div><div><h3>Main Outcome Measures</h3><div>To explore the associations between qCSF-measured CS, IC-FD%, and various AMD imaging biomarkers.</div></div><div><h3>Results</h3><div>Age-related macular degeneration exhibited significantly reduced qCSF metrics eyes across all stages compared with controls. Univariate analysis revealed significant associations between various imaging biomarkers, reduced qCSF metrics, and VA in both groups. Multivariate analysis confirmed that higher IC-FD% in the central 5 mm was significantly associated with decreases in all qCSF metrics in AMD eyes (β = −0.74 to −0.25, all <em>P</em> &lt; 0.05), but not with VA (<em>P</em> &gt; 0.05). Outer nuclear layer thickness in the central 3 mm correlated with both VA (β = 2.85, <em>P</em> &lt; 0.001) and several qCSF metrics (β = 0.01–0.90, all <em>P</em> &lt; 0.05), especially in AMD eyes. Further, larger HTD areas were associated with decreased VA (β = −0.89, <em>P</em> &lt; 0.001) and reduced CS at low-intermediate frequencies across AMD stages (β = −0.30 to −0.29, <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The significant association between IC-FD% in the central 5 mm and qCSF-measured CS reinforces the hypothesis that decreased macular choriocapillaris perfusion contributes to visual function changes in AMD, which are more pronounced in CS than in VA.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 12","pages":"Pages 1140-1150"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of 0.19-mg Fluocinolone Acetonide Implant in Postoperative Cystoid Macular Edema after Pars Plana Vitrectomy","authors":"Karolina Motloch MD, PhD ,&nbsp;Vincent Soler MD, PhD ,&nbsp;Marie-Noëlle Delyfer MD, PhD ,&nbsp;Vivien Vasseur ,&nbsp;Benjamin Wolff MD ,&nbsp;Mohamad Issa MD ,&nbsp;Corinne Dot MD, PhD ,&nbsp;Hélène Massé MD ,&nbsp;Michel Weber MD, PhD ,&nbsp;Alban Comet MD ,&nbsp;Wolfgang Hitzl PhD ,&nbsp;Frederic Matonti MD, PhD ,&nbsp;Catherine Creuzot-Garcher MD, PhD ,&nbsp;Ramin Tadayoni MD, PhD ,&nbsp;Laurent Kodjikian MD, PhD ,&nbsp;Aude Couturier MD, PhD","doi":"10.1016/j.oret.2024.07.004","DOIUrl":"10.1016/j.oret.2024.07.004","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess the efficacy and safety of 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (Iluvien) in treating chronic postoperative cystoid macular edema (PCME) after pars plana vitrectomy.</div></div><div><h3>Design</h3><div>Retrospective multicentric case series in clinical settings.</div></div><div><h3>Subjects</h3><div>Patients with chronic PCME who underwent vitrectomy in tertiary care centers in France.</div></div><div><h3>Methods</h3><div>Review of charts and OCT scans.</div></div><div><h3>Main Outcome Measures</h3><div>The primary end points were the best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Secondary end points were the intraocular pressure (IOP); proportion of patients maintaining a BCVA ≥20/40; need for additional nonstudy treatment; differences between eyes that underwent a single and multiple surgeries; and OCT biomarkers of better BCVA.</div></div><div><h3>Results</h3><div>Forty-nine eyes of 49 patients with a mean follow-up of 24.5 ± 3.87 months were included. The mean BCVA increased from 0.40 ± 0.26 logarithm of the minimum angle of resolution (logMAR) at baseline to 0.32 ± 0.24 logMAR at month 24 (<em>P</em> = 0.0035). The mean CRT decreased from 409 ± 139 μm at baseline to 340 ± 92 μm at month 24 (<em>P</em> = 0.0001). The mean IOP was 14.0 ± 4 mmHg at baseline and remained stable at 14.03 ± 4.1 mmHg at month 24 (<em>P</em> = 0.99). During the follow-up, the IOP exceeded 21 mmHg in 9 eyes, with one eye requiring cyclophotocoagulation. The BCVA was ≥20/40 in 47% of eyes (95% confidence interval [CI], 34%–61%) at baseline and in 58% of eyes at month 24 (95% CI, 41%–73%). At month 18, the likelihood of achieving a BCVA ≥20/40 was higher in eyes with intact external limiting membrane and ellipsoid zone. Additional dexamethasone (DEX) implant was injected in 14 eyes (28.6%). The treatment burden of 2.45 ± 1.35 DEX implant/y was decreased to 0.57 ± 0.60 DEX implant/y after FAc implantation (<em>P</em> = 0.001).</div></div><div><h3>Conclusions</h3><div>Fluocinolone acetonide implant improved the BCVA, reduced the CRT, and allowed reducing treatment burden in eyes with chronic PCME after vitrectomy. The safety profile was acceptable.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 12","pages":"Pages 1181-1191"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biosimilar Candidate CT-P42 in Diabetic Macular Edema","authors":"Sebastian Wolf MD, PhD ,&nbsp;Paulo-Eduardo Stanga MD, PhD ,&nbsp;Milan Veselovsky MD ,&nbsp;Miroslav Veith MD, PhD ,&nbsp;Andras Papp MD, PhD ,&nbsp;Shobhana Mange MBBS, MS(Oph) ,&nbsp;Lakshmi Kanta Mondal MBBS, MS(Oph) ,&nbsp;Dominika Romanczak MD ,&nbsp;Ladislav Janco PhD ,&nbsp;Rohan Chauhan MBBS, DO ,&nbsp;Bożena Romanowska-Dixon MD, PhD ,&nbsp;Alena Eremina MD, PhD ,&nbsp;Nataliya Zavgorodnya MD ,&nbsp;Jaroslava Dusova MD, PhD ,&nbsp;Min Sagong MD, PhD ,&nbsp;Sunghyun Kim PhD ,&nbsp;Keumyoung Ahn PhD ,&nbsp;Suyoung Kim RN, BSN ,&nbsp;Youngmin Bae DVM ,&nbsp;Sangmi Lee MS ,&nbsp;David M. Brown MD","doi":"10.1016/j.oret.2024.06.013","DOIUrl":"10.1016/j.oret.2024.06.013","url":null,"abstract":"<div><h3>Objective</h3><div>To demonstrate the therapeutic similarity of CT-P42 compared with reference aflibercept (Eylea) in adult patients with diabetic macular edema (DME).</div></div><div><h3>Design</h3><div>Randomized, active-controlled, double-masked, phase III clinical trial</div></div><div><h3>Participants</h3><div>Patients with a diagnosis of either type 1 or 2 diabetes mellitus with DME involving the center of the macula.</div></div><div><h3>Methods</h3><div>Patients were randomized (1:1) to receive either CT-P42 or reference aflibercept (2 mg/0.05 ml) by intravitreal injection every 4 weeks (5 doses), then every 8 weeks (4 doses), in the main study period. Results up to week 24 are reported herein.</div></div><div><h3>Main Outcome Measures</h3><div>The primary end point was mean change from baseline at week 8 in best-corrected visual acuity (BCVA) using the ETDRS chart. Equivalence between CT-P42 and reference aflibercept was to be concluded if the 2-sided 95% confidence interval (CI) (global assumptions) and 2-sided 90% CI (United States Food and Drug Administration [FDA] assumptions) for the treatment difference fell entirely within the equivalence margin of ±3 letters, as assessed in the full analysis set.</div></div><div><h3>Results</h3><div>Overall, 348 patients were randomized (CT-P42: 173; reference aflibercept: 175). Best-corrected visual acuity improved from baseline to week 8 in both groups, with a least squares mean (standard error) improvement of 9.43 (0.798) and 8.85 (0.775) letters in the CT-P42 and reference aflibercept groups, respectively. The estimated between-group treatment difference was 0.58 letters, with the CIs within the predefined equivalence margin of ±3 letters (95% CI, −0.73 to 1.88 [global]; 90% CI, −0.52 to 1.67 [FDA]). Through week 24, other efficacy results for the 2 groups, in terms of change in BCVA and retinal central subfield thickness, as well as ETDRS Diabetic Retinopathy Severity Scale score, supported therapeutic similarity. Pharmacokinetics, usability, safety (including the proportions of patients experiencing ≥1 treatment-emergent adverse event [CT-P42: 50.3%; reference aflibercept: 53.7%]), and immunogenicity were also comparable between groups.</div></div><div><h3>Conclusions</h3><div>This study in patients with DME demonstrated equivalence between CT-P42 and reference aflibercept (2 mg/0.05 ml) in terms of efficacy, with similar pharmacokinetic, usability, safety, and immunogenicity profiles.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 12","pages":"Pages 1163-1173"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141469808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 3-Dimensional View of Prepapillary Vascular Loop","authors":"Savithiri Palanivel DOMS, DNB,&nbsp;Prabu Baskaran MS, DNB,&nbsp;Anand Rajendran DNB, FRCS","doi":"10.1016/j.oret.2024.05.005","DOIUrl":"10.1016/j.oret.2024.05.005","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 12","pages":"Page e49"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141284368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a Recall of Intravitreal Bevacizumab: a Health Analytics in Ophthalmology Registry Review","authors":"Hasenin Al-khersan MD ,&nbsp;Elioenai Garcia BS ,&nbsp;Kenneth C. Fan MD, MBA ,&nbsp;Patrick C. Staropoli MD ,&nbsp;Edward H. Wood MD ,&nbsp;Philip Storey MD ,&nbsp;Murtaza K. Adam MD ,&nbsp;David W. Parke III MD ,&nbsp;Lawrence S. Halperin MD ,&nbsp;Kevin Quinn BS ,&nbsp;Charles C. Wykoff MD, PhD","doi":"10.1016/j.oret.2024.08.021","DOIUrl":"10.1016/j.oret.2024.08.021","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 12","pages":"Pages 1211-1213"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unilateral Multiple Choroidal Melanomas within an Area of Amelanotic Congenital Ocular Melanosis","authors":"Henry C. Skrehot BA ,&nbsp;Amer F. Alsoudi MD ,&nbsp;Amy C. Schefler MD","doi":"10.1016/j.oret.2024.05.002","DOIUrl":"10.1016/j.oret.2024.05.002","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 12","pages":"Page e47"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141284372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long Anteriorly Inserted Zonules in C1QTNF5 Gene Mutation","authors":"Raquel Félix MD, MSc ,&nbsp;João Pedro Marques MD, PhD","doi":"10.1016/j.oret.2024.05.001","DOIUrl":"10.1016/j.oret.2024.05.001","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 12","pages":"Page e46"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supplemental Intravitreal Ranibizumab Injections in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial","authors":"Jared S. Nielsen MD, MBA ,&nbsp;Andrew Chang PhD, FRANZCO ,&nbsp;Nancy M. Holekamp MD ,&nbsp;Melina Cavichini-Cordeiro MD, MS ,&nbsp;Stephanie L. Lin PhD ,&nbsp;Dominic Heinrich MD ,&nbsp;Katie F. Maass PhD ,&nbsp;Alicia Menezes MD ,&nbsp;Natasha Singh PharmD ,&nbsp;Dante J. Pieramici MD","doi":"10.1016/j.oret.2024.06.012","DOIUrl":"10.1016/j.oret.2024.06.012","url":null,"abstract":"<div><h3>Purpose</h3><div>To determine the proportion and characteristics of eyes with neovascular age-related macular degeneration (nAMD) treated with the Port Delivery System (PDS) with ranibizumab that receive supplemental intravitreal ranibizumab injections because of changes in best-corrected visual acuity (BCVA) or central subfield thickness (CST), or both, and to investigate the safety and efficacy of supplemental injections in eyes with the PDS.</div></div><div><h3>Design</h3><div>Post hoc analyses of data from the phase III, randomized, multicenter, open-label, active-comparator Archway trial (NCT03677934).</div></div><div><h3>Participants</h3><div>Adults with nAMD diagnosed within 9 months of screening previously responsive to anti-VEGF therapy.</div></div><div><h3>Intervention</h3><div>Four hundred eighteen patients were randomized to the PDS with ranibizumab 100 mg/ml with fixed refill-exchanges every 24 weeks (Q24W) or monthly intravitreal ranibizumab 0.5 mg for 96 weeks.</div></div><div><h3>Results</h3><div>Of the 246 eyes treated with the PDS Q24W and assessed for supplemental treatment criteria, the vast majority (94.6%–98.4%) did not receive supplemental treatment during each retreatment interval, with 87.4% not receiving supplemental treatment at any point during the trial. Of the 31 eyes receiving supplemental treatment, 58.1% received 1 injection and 32.3% received 2. At baseline, eyes receiving supplemental treatment were significantly more likely to have thicker retinas (mean CST, 370.5μm vs. 304.4μm; <em>P</em> = 0.0001), subretinal fluid (54.8% vs. 21.2%; <em>P</em> &lt; 0.0001), and larger pigment epithelial detachment height (215.7 μm vs. 175.9 μm; <em>P</em> = 0.003). These features have previously been associated with difficult-to-treat nAMD. Although BCVA and CST generally remained constant throughout the trial in eyes without supplemental treatment, the small number of eyes receiving supplemental treatment on average lost 1 line of vision from baseline to week 96 (mean, −5.7 ETDRS score letters) and CST continued to increase over time. Absolute BCVA at week 96 was similar irrespective of supplemental treatment status (71.1 and 73.7 letters). Best-corrected visual acuity and CST generally improved within 28 days of supplemental treatment.</div></div><div><h3>Conclusions</h3><div>Although the PDS Q24W effectively maintains vision and retinal stability in most eyes with nAMD, a small proportion of patients with features of difficult-to-treat nAMD may benefit from supplemental intravitreal anti-VEGF injections and initial close monitoring is recommended.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 12","pages":"Pages 1127-1139"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141446676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative Multimodal Imaging Characterization of Intraretinal Cysts versus Degenerative Pseudocysts in Neovascular Age-Related Macular Degeneration","authors":"Alessandro Arrigo MD, PhD ,&nbsp;Emanuela Aragona MD, PhD ,&nbsp;Maurizio Battaglia Parodi MD ,&nbsp;Francesco Bandello MD","doi":"10.1016/j.oret.2024.05.019","DOIUrl":"10.1016/j.oret.2024.05.019","url":null,"abstract":"<div><h3>Objective</h3><div>To differentiate intraretinal fluid (IRF) cysts from degenerative pseudocysts in neovascular age-related macular degeneration (AMD) by quantitative multimodal imaging.</div></div><div><h3>Design</h3><div>Observational, cross-sectional.</div></div><div><h3>Participants</h3><div>Patients affected by macular neovascularization secondary to AMD.</div></div><div><h3>Methods</h3><div>All patients were analyzed by OCT, OCT angiography (OCTA), and dense automatic real-time (ART) OCTA. New-onset cysts were considered IRF, whereas those cysts that were found to be persistent for at least 3 months were categorized as degenerative pseudocysts. Intraretinal cysts were automatically segmented to calculate cyst circularity. Peri-cyst space was quantitatively analyzed to assess the presence of perfusion signal and hyperreflective foci (HF).</div></div><div><h3>Main Outcome Measures</h3><div>Best-corrected visual acuity, cyst circularity, peri-cyst perfusion, peri-cyst HF, fibrosis, and outer retinal atrophy.</div></div><div><h3>Results</h3><div>We analyzed 387 cysts collected from 35 eyes of 35 patients with neovascular AMD (14 men; mean age, 80 ± 5 years). We classified 302 IRF cysts and 85 degenerative pseudocysts. Intraretinal fluid cysts were characterized by significantly higher circularity (0.86; range, 0.81–0.91), perfusion signal in the peri-cyst space, and peri-cyst HF in 89% of cases (all <em>P</em> &lt; 0.05). Degenerative pseudocysts showed significantly lower circularity (0.68; range, 0.64–0.76), no perfusion signal in the peri-cyst space, and peri-cyst HF in only 29% of cases (all <em>P</em> &lt; 0.05). The adopted quantitative metrics significantly correlated with disease duration, number of injections, fibrosis, and outer retinal atrophy.</div></div><div><h3>Conclusions</h3><div>Intraretinal fluid cysts can be discriminated from degenerative pseudocysts using a quantitative multimodal imaging approach. These findings are clinically relevant and should be included in future training models for artificial intelligence algorithms to improve the diagnostic power and fluid monitoring in neovascular AMD.</div></div><div><h3>Financial Disclosure(s)</h3><div>The author(s) have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 12","pages":"Pages 1118-1126"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141288373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visualizing Lenticulo-Hyaloid Anatomy","authors":"Priya Saraf MS,&nbsp;Ayush Arya MS,&nbsp;Amber Amar Bhayana MD","doi":"10.1016/j.oret.2024.04.020","DOIUrl":"10.1016/j.oret.2024.04.020","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 12","pages":"Page e45"},"PeriodicalIF":4.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141096969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}